Research progress in role of galectin-3 in heart failure

WANG Ruolin; GU Ning

doi:10.7619/jcmp.20214742

Journal of Clinical Medicine in Practice > 2022 > 26(3): 130-133, 138. > DOI: 10.7619/jcmp.20214742

WANG Ruolin, GU Ning. Research progress in role of galectin-3 in heart failure[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 130-133, 138. DOI: 10.7619/jcmp.20214742

Citation:

WANG Ruolin, GU Ning. Research progress in role of galectin-3 in heart failure[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 130-133, 138. DOI: 10.7619/jcmp.20214742

Citation:

WANG Ruolin, GU Ning. Research progress in role of galectin-3 in heart failure[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 130-133, 138. DOI: 10.7619/jcmp.20214742

PDF (715 KB)

Research progress in role of galectin-3 in heart failure

WANG Ruolin¹,
GU Ning^2, ,

1.
Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, 210046
2.
Nanjing Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, 210022

More Information

Received Date: November 30, 2021
Available Online: February 28, 2022
Published Date: February 14, 2022

Graphical Abstract

Abstract

Abstract

Heart failure (HF) is a complex clinical syndrome caused by various cardiovascular diseases. At present, the high morbidity and mortality of HF is important health problems that mankind face. Galectin-3(Gal-3) is a novel biomarker discovered in recent years, which is believed to be closely related to cardiac fibrosis, ventricular remodeling and inflammatory response, and may affect the prognosis of HF. This paper reviewed the research progress on the role of Gal-3 in HF.
- galectin-3,
- heart failure,
- biomarker,
- ventricular remodeling,
- cardiac fibrosis

FullText(HTML)

References (32)

References

[1]	《中国心血管健康与疾病报告》编写组. 《中国心血管健康与疾病报告2020》概述[J]. 中国心血管病研究, 2021, 19(7): 582-590. doi: 10.3969/j.issn.1672-5301.2021.07.002
[2]	DUMIC J, DABELIC S, FLÖGEL M. Galectin-3: an open-ended story[J]. Biochim Biophys Acta, 2006, 1760(4): 616-635. doi: 10.1016/j.bbagen.2005.12.020
[3]	FUNASAKA T, RAZ A, NANGIA-MAKKER P. Galectin-3 in angiogenesis and metastasis[J]. Glycobiology, 2014, 24(10): 886-891. doi: 10.1093/glycob/cwu086
[4]	VAN DEN BRÛLE F, CALIFICE S, CASTRONOVO V. Expression of galectins in cancer: a critical review[J]. Glycoconj J, 2002, 19(7/8/9): 537-542. https://pubmed.ncbi.nlm.nih.gov/14758077/
[5]	YANG R Y, RABINOVICH G A, LIU F T. Galectins: structure, function and therapeutic potential[J]. Expert Rev Mol Med, 2008, 10: e17. doi: 10.1017/S1462399408000719
[6]	YU F, FINLEY R L Jr, RAZ A, et al. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation[J]. J Biol Chem, 2002, 277(18): 15819-15827. https://pubmed.ncbi.nlm.nih.gov/11839755/
[7]	SHARMA U C, POKHAREL S, VAN BRAKEL T J, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J]. Circulation, 2004, 110(19): 3121-3128. doi: 10.1161/01.CIR.0000147181.65298.4D
[8]	FU H, NIE S P, LUO P, et al. Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes[J]. Biomark Med, 2020, 14(11): 943-954. doi: 10.2217/bmm-2020-0269
[9]	CALVIER L, MARTINEZ-MARTINEZ E, MIANA M, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries[J]. JACC Heart Fail, 2015, 3(1): 59-67. doi: 10.1016/j.jchf.2014.08.002
[10]	LIN Y H, CHOU C H, WU X M, et al. Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans[J]. PLoS One, 2014, 9(9): e95254. doi: 10.1371/journal.pone.0095254
[11]	SUN Z, ZHANG L L, LI L H, et al. Galectin-3 mediates cardiac remodeling caused by impaired glucose and lipid metabolism through inhibiting two pathways of activating Akt[J]. Am J Physiol Heart Circ Physiol, 2021, 320(1): H364-H380. doi: 10.1152/ajpheart.00523.2020
[12]	SHIRAKAWA K, ENDO J, KATAOKA M, et al. IL (interleukin)-10-STAT3-galectin-3 axis is essential for osteopontin-producing reparative macrophage polarization after myocardial infarction[J]. Circulation, 2018, 138(18): 2021-2035. doi: 10.1161/CIRCULATIONAHA.118.035047
[13]	IBARROLA J, ARRIETA V, SÁDABA R, et al. Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage[J]. Clin Sci (Lond), 2018, 132(13): 1471-1485. doi: 10.1042/CS20171389
[14]	HE J N, LI X H, LUO H, et al. Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4[J]. J Am Soc Hypertens, 2017, 11(5): 275-289, e2. doi: 10.1016/j.jash.2017.03.008
[15]	HEYMANS S, GONZÁLEZ A, PIZARD A, et al. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential[J]. Eur J Heart Fail, 2015, 17(8): 764-771. doi: 10.1002/ejhf.312
[16]	LIU Y H, D'AMBROSIO M, LIAO T D, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin[J]. Am J Physiol Heart Circ Physiol, 2009, 296(2): H404-H412. doi: 10.1152/ajpheart.00747.2008
[17]	BLANCHARD H, YU X, COLLINS P M, et al. Galectin-3 inhibitors: a patent review (2008-present)[J]. Expert Opin Ther Pat, 2014, 24(10): 1053-1065. doi: 10.1517/13543776.2014.947961
[18]	VERGARO G, PRUD'HOMME M, FAZAL L, et al. Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice[J]. Hypertension, 2016, 67(3): 606-612. doi: 10.1161/HYPERTENSIONAHA.115.06161
[19]	XU G R, ZHANG C, YANG H X, et al. Modified Citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway[J]. Biomedecine Pharmacother, 2020, 126: 110071. doi: 10.1016/j.biopha.2020.110071
[20]	YU L L, RUIFROK W P, MEISSNER M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis[J]. Circ Heart Fail, 2013, 6(1): 107-117. doi: 10.1161/CIRCHEARTFAILURE.112.971168
[21]	张记收, 王梦龙, 刘剑芳, 等. 半乳糖凝集素3对心力衰竭诊断价值的Meta分析[J]. 中国循证心血管医学杂志, 2020, 12(1): 14-17, 23. doi: 10.3969/j.issn.1674-4055.2020.01.04
[22]	TRIPPEL T D, MENDE M, DVNGEN H D, et al. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study[J]. ESC Heart Fail, 2021, 8(2): 829-841. doi: 10.1002/ehf2.13174
[23]	FRENCH B, WANG L, KY B, et al. Prognostic value of galectin-3 for adverse outcomes in chronic heart failure[J]. J Card Fail, 2016, 22(4): 256-262. doi: 10.1016/j.cardfail.2015.10.022
[24]	DE BOER R A, VAN VELDHUISEN D J, GANSEVOORT R T, et al. The fibrosis marker galectin-3 and outcome in the general population[J]. J Intern Med, 2012, 272(1): 55-64. doi: 10.1111/j.1365-2796.2011.02476.x
[25]	WU C X, LV Z T, LI X Y, et al. Galectin-3 in predicting mortality of heart failure: a systematic review and meta-analysis[J]. Heart Surg Forum, 2021, 24(2): E327-E332. doi: 10.1532/hsf.3547
[26]	IMRAN T F, SHIN H J, MATHENGE N, et al. Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population[J]. Am J Cardiol, 2017, 119(1): 57-64. doi: 10.1016/j.amjcard.2016.09.019
[27]	YANCY C W, JESSUP M, BOZKURT B, et al. 2013 ACCF/AHA guideline for the management of heart failure[J]. J Am Coll Cardiol, 2013, 62(16): e147-e239. doi: 10.1016/j.jacc.2013.05.019
[28]	GEHLKEN C, SUTHAHAR N, MEIJERS W C, et al. Galectin-3 in heart failure[J]. Heart Fail Clin, 2018, 14(1): 75-92. doi: 10.1016/j.hfc.2017.08.009
[29]	BESLER C, LANG D, URBAN D, et al. Plasma and cardiac galectin-3 in patients with heart failure reflects both inflammation and fibrosis: implications for its use as a biomarker[J]. Circ Heart Fail, 2017, 10(3): e003804. doi: 10.1161/CIRCHEARTFAILURE.116.003804
[30]	詹文凤. 慢性心力衰竭中医证型与Gal-3关系的研究[D]. 福建中医药大学, 2020.
[31]	史菲, 罗海明. 半乳糖凝集素-3在慢性充血性心力衰竭中的临床价值及与中医分型的相关性研究[J]. 中西医结合心脑血管病杂志, 2013, 12(12): 1409-1411. doi: 10.3969/j.issn.1672-1349.2013.12.001
[32]	聂锦坤, 陈俊, 仲景. 温阳活血利水法治疗慢性心力衰竭急性加重患者的临床疗效及对心功能和血清可溶性肿瘤因子2抑制剂、半乳糖凝集素-3的影响[J]. 河北中医, 2021, 43(2): 247-251. doi: 10.3969/j.issn.1002-2619.2021.02.016

Cited By

Get Citation

PDF

XML

Article views (384) PDF downloads (25)

Turn off MathJax

Article Contents

Abstract

References

Research progress in role of galectin-3 in heart failure

Abstract

References

Catalog

Export File

Citation

Format

Content